KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Long-Term Debt Issuances (2016 - 2025)

Historic Long-Term Debt Issuances for Gsk (GSK) over the last 14 years, with Q3 2025 value amounting to -$5.4 million.

  • Gsk's Long-Term Debt Issuances changed N/A to -$5.4 million in Q3 2025 from the same period last year, while for Dec 2025 it was $2.5 billion, marking a year-over-year increase of 10954.71%. This contributed to the annual value of $2.6 billion for FY2025, which is 8991.94% up from last year.
  • Gsk's Long-Term Debt Issuances amounted to -$5.4 million in Q3 2025.
  • Over the past 5 years, Gsk's Long-Term Debt Issuances peaked at $12.4 billion during Q1 2022, and registered a low of -$23.2 billion during Q2 2022.
  • In the last 4 years, Gsk's Long-Term Debt Issuances had a median value of -$161.7 million in 2023 and averaged -$1.4 billion.
  • Its Long-Term Debt Issuances has fluctuated over the past 5 years, first skyrocketed by 7697.85% in 2023, then plummeted by 39851.15% in 2024.
  • Quarter analysis of 4 years shows Gsk's Long-Term Debt Issuances stood at -$1.2 billion in 2022, then skyrocketed by 76.98% to -$276.8 million in 2023, then plummeted by 398.51% to -$1.4 billion in 2024, then surged by 99.61% to -$5.4 million in 2025.
  • Its Long-Term Debt Issuances was -$5.4 million in Q3 2025, compared to -$46.7 million in Q2 2025 and $2.5 billion in Q1 2025.